| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0140-6736(01)05842-1 |
| P698 | PubMed publication ID | 11551598 |
| P2093 | author name string | D R Owens | |
| G B Bolli | |||
| B Zinman | |||
| P2860 | cites work | Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 |
| The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group | Q27861088 | ||
| Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal-bolus therapy. | Q32050034 | ||
| Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes | Q33180598 | ||
| Hypoglycemia and insulin analogues: is there a reduction in the incidence? | Q33702647 | ||
| Insulin analogues and their potential in the management of diabetes mellitus | Q33753661 | ||
| Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus. A randomized, controlled trial | Q33844615 | ||
| Insulin analogs with improved pharmacokinetic profiles | Q33933381 | ||
| Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study | Q34720231 | ||
| NovoSol Basal: pharmacokinetics of a novel soluble long acting insulin analogue | Q35714943 | ||
| Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group | Q36244558 | ||
| The physiologic replacement of insulin. An elusive goal | Q38662052 | ||
| Insulin Pharmacokinetics | Q40179848 | ||
| The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin | Q41047515 | ||
| Growth promoting and metabolic activity of the human insulin analogue [GlyA21,ArgB31,ArgB32]insulin (HOE 901) in muscle cells | Q41128080 | ||
| Insulin lispro. | Q41528865 | ||
| Metabolic and immunologic effects of insulin lispro in gestational diabetes | Q41689564 | ||
| Sustained signalling from the insulin receptor after stimulation with insulin analogues exhibiting increased mitogenic potency | Q42177647 | ||
| Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group | Q42612090 | ||
| Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin | Q43584177 | ||
| Insulin aspart: a novel rapid-acting human insulin analogue | Q47614726 | ||
| Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellitus: importance of appropriate replacement of basal insulin and time-interval injection-meal | Q47756459 | ||
| Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps | Q48008296 | ||
| Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidøre Study Group on Childhood Diabetes. | Q50866522 | ||
| Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. | Q51018348 | ||
| A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. | Q51552514 | ||
| Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. | Q51554474 | ||
| Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. | Q51554477 | ||
| Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes. | Q51556027 | ||
| A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. | Q51556699 | ||
| Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. | Q51557344 | ||
| Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers. | Q51562737 | ||
| Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. | Q51564469 | ||
| Optimization of evening insulin dose in patients using the short-acting insulin analog lispro. | Q51569204 | ||
| Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. | Q52232111 | ||
| Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group. | Q53346037 | ||
| Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial. | Q53899946 | ||
| Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. | Q53954682 | ||
| Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. | Q53974364 | ||
| Study of porcine and human isophane (NPH) insulins in normal subjects. | Q54062014 | ||
| Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men: comparison with NPH insulin and the influence of different subcutaneous injection sites. | Q55033955 | ||
| Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. | Q55034466 | ||
| Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting insulin HOE 901 as part of a three-injection regimen | Q58811242 | ||
| Lispro or regular insulin for multiple injection therapy in adolescence. Differences in free insulin and glucose levels overnight | Q58811249 | ||
| Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients | Q61684872 | ||
| Variation in125i-insulin absorption and blood glucose concentration | Q66960342 | ||
| Use of premixed insulin among the elderly. Reduction of errors in patient preparation of mixtures | Q67969412 | ||
| The effect of mixing human soluble and human crystalline zinc-suspension insulin: plasma insulin and blood glucose profiles after subcutaneous injection | Q70027694 | ||
| Reduced Solubility of Short-Acting Soluble Insulins when Mixed with Longer-Acting Insulins | Q70307806 | ||
| Demonstration of a relatively hepatoselective effect of covalent insulin dimers on glucose metabolism in dogs | Q70978291 | ||
| Effects of the short-acting insulin analog [Lys(B28),Pro(B29)] on postprandial blood glucose control in IDDM | Q71694238 | ||
| Insulin analogues | Q71955789 | ||
| [Lys(B28), Pro(B29)]-human insulin. A rapidly absorbed analogue of human insulin | Q72787246 | ||
| Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart | Q73014285 | ||
| Insulin lispro in CSII: results of a double-blind crossover study | Q73070889 | ||
| Inadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens | Q73179764 | ||
| Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor | Q73226153 | ||
| Modifications in the B10 and B26-30 regions of the B chain of human insulin alter affinity for the human IGF-I receptor more than for the insulin receptor | Q73567698 | ||
| Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes | Q73840597 | ||
| Optimized basal-bolus therapy using a fixed mixture of 75% lispro and 25% NPL insulin in type 1 diabetes patients: no favorable effects on glycemic control, physiological responses to hypoglycemia, well-being, or treatment satisfaction | Q73840618 | ||
| Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo | Q73840622 | ||
| Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use | Q73922459 | ||
| Effect of fatty acids and selected drugs on the albumin binding of a long-acting, acylated insulin analogue | Q74017384 | ||
| Rapid appearance and onset of action of insulin aspart in paediatric subjects with type 1 diabetes | Q74100700 | ||
| Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime | Q74655503 | ||
| Effectiveness of human ultralente versus NPH insulin in providing basal insulin replacement for an insulin lispro multiple daily injection regimen. A double-blind randomized prospective trial. The Canadian Lispro Study Group | Q77216592 | ||
| Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections | Q77374253 | ||
| Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304 | Q77374258 | ||
| Optimal provision of daytime NPH insulin in patients using the insulin analog lispro | Q77417151 | ||
| Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes | Q77417168 | ||
| Novel hepatoselective insulin analogues: studies with covalently linked thyroxyl-insulin complexes | Q77597434 | ||
| Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime | Q77761932 | ||
| Optimal administration of lispro insulin in hyperglycemic type 1 diabetes | Q77765004 | ||
| New concept for long-acting insulin: spontaneous conversion of an inactive modified insulin to the active hormone in circulation: 9-fluorenylmethoxycarbonyl derivative of insulin | Q77948226 | ||
| P433 | issue | 9283 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 739-746 | |
| P577 | publication date | 2001-09-01 | |
| P1433 | published in | The Lancet | Q939416 |
| P1476 | title | Insulins today and beyond | |
| P478 | volume | 358 |
| Q90682790 | A forskolin-conjugated insulin analog targeting endogenous glucose-transporter for glucose-responsive insulin delivery |
| Q35828121 | A practical approach for implementation of a basal-prandial insulin therapy regimen in patients with type 2 diabetes |
| Q40476995 | A test of the reliability and validity of a diabetes specific quality of life scale in a Nigerian hospital. |
| Q61607023 | Accès à l’insuline dans les pays en voie de développement : une problématique complexe |
| Q36636422 | Achieving fasting and postprandial blood glucose control in type 2 diabetes |
| Q36416211 | Addition of rapid-acting insulin to basal insulin therapy in type 2 diabetes: indications and modalities |
| Q44250993 | Addressing the epidemic: pharmacotherapeutic management of diabetes in women |
| Q44877496 | Advances in bioresponsive closed-loop drug delivery systems |
| Q90354103 | Advances in transdermal insulin delivery |
| Q35591065 | Alternative routes of insulin delivery |
| Q61443550 | Applications of stem cells and bioprinting for potential treatment of diabetes |
| Q37890774 | Basal insulin: physiology, pharmacology, and clinical implications |
| Q45118534 | Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin |
| Q52373088 | Bioresponsive Microneedles with a Sheath Structure for H2 O2 and pH Cascade-Triggered Insulin Delivery. |
| Q27000550 | Cell factories for insulin production |
| Q37371427 | Central leptin gene therapy ameliorates diabetes type 1 and 2 through two independent hypothalamic relays; a benefit beyond weight and appetite regulation |
| Q37632407 | Challenges and advances in nanoparticle-based oral insulin delivery. |
| Q41363134 | Chemical and Biological Aspects of Extracts from Medicinal Plants with Antidiabetic Effects |
| Q37030775 | Clinical pharmacokinetics and pharmacodynamics of insulin glulisine |
| Q28540671 | Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review |
| Q37235857 | Comparison of a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) in type 1 diabetes: a randomized open parallel multicenter study. |
| Q35629797 | Comparison of anti-diabetic drug prescribing in children and adolescents in seven European countries |
| Q57951508 | Comparison of the pharmacokinetics and pharmacodynamics of biphasic insulin aspart and insulin glargine in people with type 2 diabetes |
| Q46563558 | Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir vs. morning plus bedtime NPH insulin |
| Q44655654 | Comparison of thrice daily ‘high’ vs. ‘medium’ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes |
| Q38665753 | Controlled release of biologics for the treatment of type 2 diabetes |
| Q49889663 | Core-Shell Microneedle Gel for Self-Regulated Insulin Delivery. |
| Q41564970 | Degludec: the new ultra-long insulin analogue |
| Q35753538 | Development of secreted proteins as biotherapeutic agents |
| Q51245935 | EADSG Guidelines: Insulin Therapy in Diabetes. |
| Q42056712 | Effect of thyroid hormone binding proteins on insulin receptor binding of B1-thyronine-insulin analogues |
| Q64269628 | Effects of Periodic Intensive Insulin Therapy: An Updated Review |
| Q44953752 | Effects of QD insulin detemir or neutral protamine Hagedorn on blood glucose control in patients with type I diabetes mellitus using a basal-bolus regimen |
| Q38195730 | Emerging micro- and nanotechnology based synthetic approaches for insulin delivery |
| Q57436349 | Engineering Synthetic Insulin-Secreting Cells Using Hyaluronic Acid Microgels Integrated with Glucose-Responsive Nanoparticles |
| Q80442179 | Engineering predictability and protraction in a basal insulin analogue: the pharmacology of insulin detemir |
| Q34299641 | Evaluation of insulin regimens as an effective option for glycemic control in patients with type 2 diabetes: A propensity score-matched cohort study across Japan (JDDM31) |
| Q79263434 | From the coalface: does glargine insulin improve hypoglycaemic episodes, glycaemic control or affect body mass in type 1 diabetic subjects who are attending a 'routine' diabetes clinic? |
| Q35011714 | Ghrelin in the regulation of body weight and metabolism |
| Q44870456 | Glucose-Responsive Insulin Delivery by Microneedle-Array Patches Loaded with Hypoxia-Sensitive Vesicles |
| Q88921796 | Glucose-Responsive Microneedle Patches for Diabetes Treatment |
| Q44875590 | Glucose-responsive insulin by molecular and physical design |
| Q89518612 | Glucose-responsive insulin patch for the regulation of blood glucose in mice and minipigs |
| Q40629104 | Hepatic expression of the human insulin gene reduces glucose levels in vivo in diabetic mice model |
| Q80224384 | How effective is biphasic insulin aspart in the treatment of adolescents with type 1 diabetes? |
| Q36359175 | How to achieve a predictable basal insulin? |
| Q36507652 | How well do rapid-acting insulins work in obese individuals? |
| Q44074369 | Hybrid insulin cocrystals for controlled release delivery |
| Q37071750 | Impact of therapeutic advances on hypoglycaemia in type 2 diabetes |
| Q37595832 | Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion |
| Q42744272 | Injectable nano-network for glucose-mediated insulin delivery |
| Q42611726 | Insulin Detemir Is Characterized by a Consistent Pharmacokinetic Profile Across Age-Groups in Children, Adolescents, and Adults With Type 1 Diabetes |
| Q37235879 | Insulin analogs versus human insulin in the treatment of patients with diabetic ketoacidosis: a randomized controlled trial |
| Q37921892 | Insulin analogs versus human insulin in type 2 diabetes |
| Q35164710 | Insulin analogues and other developments in insulin therapy for diabetes |
| Q39895082 | Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells |
| Q53535262 | Insulin analogues display atypical differentiative activities in skin keratinocytes. |
| Q57413008 | Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes |
| Q36013053 | Insulin detemir--a new basal insulin analog |
| Q36150729 | Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes |
| Q31122518 | Insulin nanoparticles: a novel formulation approach for poorly water soluble Zn-insulin |
| Q35915921 | Insulin strategies for type 2 diabetes mellitus |
| Q36092959 | Insulin therapy in pregnancy complicated by diabetes: are insulin analogs a new tool? |
| Q34524568 | Insulin therapy: optimizing control in type 1 and type 2 diabetes |
| Q44871115 | Insulin-Responsive Glucagon Delivery for Prevention of Hypoglycemia |
| Q39309680 | Insulin-associated weight gain in obese type 2 diabetes mellitus patients: What can be done? |
| Q34453173 | Insulinotropic meglitinide analogues |
| Q37443837 | Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes |
| Q38573431 | Issues in the provision of nursing care to people undergoing cardiac surgery who also have type 2 diabetes |
| Q37778403 | Leptin gene therapy in the fight against diabetes |
| Q36575356 | Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal-bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial |
| Q55039919 | Mechanistic perspective and functional activity of insulin in amylin aggregation. |
| Q51567062 | Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes: continuous subcutaneous insulin infusion versus injection therapy. |
| Q34481917 | Microneedle-array patches loaded with hypoxia-sensitive vesicles provide fast glucose-responsive insulin delivery |
| Q37206883 | Microneedles Integrated with Pancreatic Cells and Synthetic Glucose-Signal Amplifiers for Smart Insulin Delivery |
| Q30437728 | Minimizing hypoglycemia while maintaining glycemic control in diabetes |
| Q53636879 | NIR upconversion fluorescence glucose sensing and glucose-responsive insulin release of carbon dot-immobilized hybrid microgels at physiological pH. |
| Q26779447 | Nanoparticle based insulin delivery system: the next generation efficient therapy for Type 1 diabetes |
| Q34743230 | New horizons--alternative routes for insulin therapy |
| Q35611319 | New insulin analogues and their impact on diabetes care |
| Q33488897 | Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses |
| Q37199330 | Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus |
| Q34532529 | Oral delivery of insulin for treatment of diabetes: status quo, challenges and opportunities |
| Q36645386 | Outcomes with insulin glargine in patients with type 2 diabetes previously on NPH insulin: evidence from clinical practice in Spain |
| Q37035503 | Perinatal outcomes associated with the use of glargine during pregnancy |
| Q44627220 | Pharmacokinetic and pharmacodynamic properties of insulin aspart and human insulin |
| Q37826342 | Pivotal role of leptin-hypothalamus signaling in the etiology of diabetes uncovered by gene therapy: a new therapeutic intervention? |
| Q85200265 | Real-life dosage and clinical efficacy of biphasic insulin preparations in patients with type 2 diabetes |
| Q38963291 | Regulatory Forum Opinion Piece: Review-Toxicological Pathology Profile and Regulatory Expectations for Nonclinical Development of Insulins and Insulin Analogues |
| Q24654974 | Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study |
| Q57658296 | Shiftwork and Higher Pancreatic Secretion: Early Detection of an Intermediate State of Insulin Resistance? |
| Q37296843 | Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study |
| Q38805344 | Simultaneous expression and transportation of insulin by supramolecular polysaccharide nanocluster |
| Q38309879 | Solid-state protein formulations |
| Q50904654 | Stimuli-Responsive Delivery of Therapeutics for Diabetes Treatment. |
| Q104289620 | Study on the Influencing Factors of Hypoglycemic Effect of Folate Targeted Polymersomes Encapsulating Insulin |
| Q44410267 | Tetracycline-regulated secretion of human insulin in transfected primary myoblasts |
| Q57599459 | The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin |
| Q35087622 | The utility and efficacy of the new insulins in the management of diabetes and pregnancy |
| Q41459607 | Three-chain insulin analogs demonstrate the importance of insulin secondary structure to bioactivity |
| Q28301396 | Type 1 diabetes |
| Q30410088 | Ultrasound-triggered regulation of blood glucose levels using injectable nano-network. |
| Q37857686 | Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin |
Search more.